NEW YORK and CAESAREA, Israel, Nov.
15, 2019 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a leading
global, digital therapeutics company, presented new clinical data
yesterday at the 19th Annual Diabetes Technology Meeting
("DTM") conference in Bethesda,
Maryland, which showed remarkable improvements in average
blood glucose levels (BGavg) and in-range measurements in patients
with diabetes using Dario's digital therapeutics platform and
dedicated one-on-one personal health coaching.
DarioHealth's digital therapeutics platform delivers
personalized, evidence-based interventions to users that are driven
by precision data analytics, high quality software and one-on-one
coaching, which are all available through Dario's suite of
membership plans. The clinical study data presented at the DTM
conference included users enrolled in Dario's full membership plan,
which is available to payers, providers and consumers.
The objective of the study was to examine whether digital
interventions, based on the Dario system, contribute to better
diabetes management. The results suggest that personal health
coaching, combined with regular health information captured on the
Dario app, such as blood glucose levels, food and exercise, can
significantly assist diabetes patients in managing and improving
their chronic condition, potentially lowering their blood glucose
levels to be in line with the American Diabetes Association (ADA)
suggested A1c goals of 6.5% or less (equivalent to 140 mg/dL blood
glucose average) for certain diabetic patients.
The Dario study was based on an analysis of clinical data of 162
Dario users. In order to establish a baseline blood glucose level
prior to commencement of the study, the Dario users study group
consistently measured their blood glucose levels for one month
prior to starting the Dario personal coaching program. Once the
study began, these users received regular digital monitoring of
their blood glucose levels throughout the day and direct personal
coaching support from a Dario health coach for three months, while
measuring their blood glucose levels more than 30 times per month,
on average, throughout the study.
The clinical outcomes observed showed that Dario's blood glucose
monitoring system, coupled with personal Dario coaching,
successfully assisted a large percentage of users in managing their
blood glucose levels to be in line with what would be considered
pre-diabetes levels:
- 45% (73 out of 162) of the study group reduced their average
blood glucose levels to under 140 mg/dL, which is considered a
pre-diabetic measurement according to ADA guidelines;
- All study users (162 cohort) reduced their blood glucose levels
by an average of 6% (155±42.1 mg/dL) while participating in the
three-month study (compared to a baseline level of 165±48.7
mg/dL);
- Subgroup analyses of 101 users out of 162 started with BGavg
>140mg/dL revealed an increase of 19% in % in-range
(70-180mg/dL) measurements of the total measurements when compared
to the baseline on average (65% vs. 54%);
- Moreover, 51 users considered "high risk" (started with BGavg
>180 mg/dL) increased their % in-range measurements by 38% (48%
vs. 35%) and reduced their BGavg by 14% (192±39 vs. 224±38) on
average.
Olivier Jarry, President and
Chief Commercial Officer at DarioHealth, commented on the study
saying, "It is a great honor to present these results, which we
believe show that patients using Dario's digital intervention
platform, combined with consistent digital monitoring of blood
glucose and personal coaching along with other health and lifestyle
parameters, leads to increased user engagement and better health
outcomes for individuals with diabetes."
"At DarioHealth, our objective is to help users achieve
meaningful outcomes and improved chronic disease self-management.
We believe that the results of this study provide further evidence
of the real value that our program delivers to our users by
promoting better understanding of their chronic condition
management," said Erez Raphael,
Chief Executive Officer of DarioHealth.
"We believe that these study results further prove that Dario's
diabetes solutions can assist users in modifying their behavior to
achieve improved glycemic levels. A blood glucose level of less
than 140mg/dL is an important threshold for a diabetes patient. The
ADA suggests stringent A1c goals of 6.5% (equivalent to 140 mg/dL)
for certain diabetic patients, if such levels can be achieved
without significant hypoglycemia. Moreover, retaining blood glucose
at targeted ADA levels helps people with diabetes avoid serious
complications from their health condition," said Mr. Raphael.
Dario offers a digital blood glucose monitoring system
accessible through its mobile phone app; modules to regularly
monitor medication, weight, blood pressure, food and exercise;
weekly progress reports; personalized coaching guidance for
individual users; feedback alerts; relevant content delivery and
follow-up with dedicated professionals via in-app chats features,
emails and calls. We believe that the results of the study show
that combining digital and human coaching can be an effective tool
in promoting user self-care, which is a central goal of Dario. The
system helps users understand their real-time clinical status, the
cause and effect of different behaviors and how to best manage
better their condition and improve their clinical outcomes.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading,
global digital therapeutics company revolutionizing the way
people with chronic conditions manage their health. By delivering
evidence-based interventions that are driven by data, high-quality
software and coaching, we empower individuals to make healthy
adjustments to their daily lifestyle choices to improve their
overall health. Our cross-functional team operates at the
intersection of life sciences, behavioral science and software
technology to deliver highly engaging therapeutic interventions.
Dario is one of the highest-rated diabetes solutions in the market,
and its user-centric MyDario™ mobile app is loved by tens of
thousands of consumers around the globe. DarioHealth is rapidly
moving into new chronic conditions and geographic markets, using a
performance-based approach to improve the health of users managing
chronic disease. To learn more about DarioHealth and its digital
health solutions, please go
to: http://mydario.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that the study results suggest that personal health coaching,
combined with regular health information captured on the Dario app,
such as blood glucose levels, food and exercise, can significantly
assist diabetes patients in managing and improving their chronic
condition, potentially lowering their blood glucose levels to be in
line with the AD) suggested A1c goals of 6.5% or less (equivalent
to 140 mg/dL blood glucose average) for certain diabetic patients,
the belief that the study results show that patients using Dario's
digital intervention platform, combined with consistent digital
monitoring of blood glucose and personal coaching along with other
health and lifestyle parameters, leads to increased user engagement
and better health outcomes for individuals with diabetes, the
belief that the results of the study provide further evidence of
the real value that the Company's program delivers to its users by
promoting better understanding of their chronic condition
management and the belief that the study results show that
combining digital and human coaching can be an effective tool in
promoting user self-care, it is using forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario)
may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact:
Claudia
Levi
Content & Communications Manager
claudia@mydario.com
+1-347-767-4220
View original
content:http://www.prnewswire.com/news-releases/dariohealth-clinical-study-data-highlights-the-material-benefit-digital-interventions-have-on-glycemic-control-in-users-with-diabetes-300959113.html
SOURCE DarioHealth Corp.